279 related articles for article (PubMed ID: 24903767)
1. New-onset mediastinal and central nervous system sarcoidosis in a patient with metastatic melanoma undergoing CTLA4 monoclonal antibody treatment.
Murphy KP; Kennedy MP; Barry JE; O'Regan KN; Power DG
Oncol Res Treat; 2014; 37(6):351-3. PubMed ID: 24903767
[TBL] [Abstract][Full Text] [Related]
2. Sarcoidosis Following Anti-PD-1 and Anti-CTLA-4 Therapy for Metastatic Melanoma.
Reddy SB; Possick JD; Kluger HM; Galan A; Han D
J Immunother; 2017 Oct; 40(8):307-311. PubMed ID: 28737620
[TBL] [Abstract][Full Text] [Related]
3. Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy.
Tan I; Malinzak M; Salama AKS
J Immunother Cancer; 2018 Jul; 6(1):77. PubMed ID: 30064495
[TBL] [Abstract][Full Text] [Related]
4. Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer.
Graziani G; Tentori L; Navarra P
Pharmacol Res; 2012 Jan; 65(1):9-22. PubMed ID: 21930211
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases.
Di Giacomo AM; Danielli R; Guidoboni M; Calabrò L; Carlucci D; Miracco C; Volterrani L; Mazzei MA; Biagioli M; Altomonte M; Maio M
Cancer Immunol Immunother; 2009 Aug; 58(8):1297-306. PubMed ID: 19139884
[TBL] [Abstract][Full Text] [Related]
6. Management of immune-related adverse events and kinetics of response with ipilimumab.
Weber JS; Kähler KC; Hauschild A
J Clin Oncol; 2012 Jul; 30(21):2691-7. PubMed ID: 22614989
[TBL] [Abstract][Full Text] [Related]
7. Sarcoidosis-like syndrome and lymphadenopathy due to checkpoint inhibitors.
Firwana B; Ravilla R; Raval M; Hutchins L; Mahmoud F
J Oncol Pharm Pract; 2017 Dec; 23(8):620-624. PubMed ID: 27590328
[TBL] [Abstract][Full Text] [Related]
8. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network.
Voskens CJ; Goldinger SM; Loquai C; Robert C; Kaehler KC; Berking C; Bergmann T; Bockmeyer CL; Eigentler T; Fluck M; Garbe C; Gutzmer R; Grabbe S; Hauschild A; Hein R; Hundorfean G; Justich A; Keller U; Klein C; Mateus C; Mohr P; Paetzold S; Satzger I; Schadendorf D; Schlaeppi M; Schuler G; Schuler-Thurner B; Trefzer U; Ulrich J; Vaubel J; von Moos R; Weder P; Wilhelm T; Göppner D; Dummer R; Heinzerling LM
PLoS One; 2013; 8(1):e53745. PubMed ID: 23341990
[TBL] [Abstract][Full Text] [Related]
9. [Orbital myositis associated with ipilimumab].
Lecouflet M; Verschoore M; Giard C; Gohier P; Le Corre Y; Milea D; Martin L
Ann Dermatol Venereol; 2013; 140(6-7):448-51. PubMed ID: 23773743
[TBL] [Abstract][Full Text] [Related]
10. Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management.
Kaehler KC; Piel S; Livingstone E; Schilling B; Hauschild A; Schadendorf D
Semin Oncol; 2010 Oct; 37(5):485-98. PubMed ID: 21074064
[TBL] [Abstract][Full Text] [Related]
11. Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: Effectiveness and toxicity management.
Savoia P; Astrua C; Fava P
Hum Vaccin Immunother; 2016 May; 12(5):1092-101. PubMed ID: 26889818
[TBL] [Abstract][Full Text] [Related]
12. Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: Increased rate and mimicker of metastasis.
Chorti E; Kanaki T; Zimmer L; Hadaschik E; Ugurel S; Gratsias E; Roesch A; Bonella F; Wessendorf TE; Wälscher J; Theegarten D; Schadendorf D; Livingstone E
Eur J Cancer; 2020 May; 131():18-26. PubMed ID: 32248071
[TBL] [Abstract][Full Text] [Related]
13. A case report of orbital inflammatory syndrome secondary to ipilimumab.
Henderson AD; Thomas DA
Ophthalmic Plast Reconstr Surg; 2015; 31(3):e68-70. PubMed ID: 24814274
[TBL] [Abstract][Full Text] [Related]
14. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy.
Hoos A; Ibrahim R; Korman A; Abdallah K; Berman D; Shahabi V; Chin K; Canetta R; Humphrey R
Semin Oncol; 2010 Oct; 37(5):533-46. PubMed ID: 21074069
[TBL] [Abstract][Full Text] [Related]
15. Anti-CTLA4 monoclonal antibody induced sarcoidosis in a metastatic melanoma patient.
Eckert A; Schoeffler A; Dalle S; Phan A; Kiakouama L; Thomas L
Dermatology; 2009; 218(1):69-70. PubMed ID: 18832811
[No Abstract] [Full Text] [Related]
16. Combination Anti-CTLA-4 and Anti-RANKL in Metastatic Melanoma.
Smyth MJ; Yagita H; McArthur GA
J Clin Oncol; 2016 Apr; 34(12):e104-6. PubMed ID: 25311221
[No Abstract] [Full Text] [Related]
17. [Endocrinologic side effects of oncologic treatment with anti-CTLA-4-antibodies].
Fischli S; Allelein S; Zander T; Henzen C
Dtsch Med Wochenschr; 2014 May; 139(19):996-1000. PubMed ID: 24782152
[TBL] [Abstract][Full Text] [Related]
18. Nivolumab-Induced Sarcoid-Like Granulomatous Reaction in a Patient With Advanced Melanoma.
Danlos FX; Pagès C; Baroudjian B; Vercellino L; Battistella M; Mimoun M; Jebali M; Bagot M; Tazi A; Lebbé C
Chest; 2016 May; 149(5):e133-6. PubMed ID: 27157227
[TBL] [Abstract][Full Text] [Related]
19. Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma.
Lipson EJ; Drake CG
Clin Cancer Res; 2011 Nov; 17(22):6958-62. PubMed ID: 21900389
[TBL] [Abstract][Full Text] [Related]
20. Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanoma.
Kähler KC; Hauschild A
J Dtsch Dermatol Ges; 2011 Apr; 9(4):277-86. PubMed ID: 21083648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
